PE61699A1 - Composicion farmaceutica de lamivudina - Google Patents

Composicion farmaceutica de lamivudina

Info

Publication number
PE61699A1
PE61699A1 PE1998000203A PE00020398A PE61699A1 PE 61699 A1 PE61699 A1 PE 61699A1 PE 1998000203 A PE1998000203 A PE 1998000203A PE 00020398 A PE00020398 A PE 00020398A PE 61699 A1 PE61699 A1 PE 61699A1
Authority
PE
Peru
Prior art keywords
lamivudine
derivative
refers
pharmaceutical composition
parabene
Prior art date
Application number
PE1998000203A
Other languages
English (en)
Inventor
Ngoc-Anh Thi Nguyen
Warren Michael Casey
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706295.4A external-priority patent/GB9706295D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE61699A1 publication Critical patent/PE61699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION DE ADMINISTRACION ORAL QUE COMPRENDE LAMIVUDINA O SU DERIVADO Y UN CONSERVADOR. CARACTERIZADA POR: a)ESTAR LIBRE DE ETANOL Y EDTA, b)UN pH MAYOR DE 5,5, DE PREFERENCIA pH ES 6; c)EXHIBE EFICACIA DE CONSERVACION ANTIMICROBIANA; d)COMPRENDE UN SEGUNDO AGENTE TERAPEUTICO. PARTICULARMENTE EL CONSERVADOR ES METILPARABENO Y PROPILPARABENO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE PONER EN ASOCIACION LA LAMIVUDINA O SU DERIVADO CON UN PORTADOR. LA COMPOSICION PUEDE SER UTIL PARA LA PROFILAXIS O EL TRATAMIENTO DE INFECCIONES VIRALES COMO VIH O VIRUS DE HEPATITIS B
PE1998000203A 1997-03-24 1998-03-20 Composicion farmaceutica de lamivudina PE61699A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4235397P 1997-03-24 1997-03-24
GBGB9706295.4A GB9706295D0 (en) 1997-03-26 1997-03-26 Lamivudine formulation

Publications (1)

Publication Number Publication Date
PE61699A1 true PE61699A1 (es) 1999-07-08

Family

ID=26311267

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000203A PE61699A1 (es) 1997-03-24 1998-03-20 Composicion farmaceutica de lamivudina

Country Status (40)

Country Link
US (1) US6004968A (es)
EP (1) EP0969815B1 (es)
JP (1) JP3264937B2 (es)
KR (1) KR100484695B1 (es)
CN (1) CN1191061C (es)
AP (1) AP1141A (es)
AR (1) AR011697A1 (es)
AT (1) ATE295150T1 (es)
AU (1) AU728461B2 (es)
BG (1) BG64690B1 (es)
BR (1) BR9808060B1 (es)
CA (1) CA2286126C (es)
CO (1) CO4980849A1 (es)
CY (1) CY2569B1 (es)
CZ (1) CZ298008B6 (es)
DE (1) DE69830154T2 (es)
EA (1) EA001990B1 (es)
EE (1) EE03996B1 (es)
ES (1) ES2239802T3 (es)
HK (1) HK1022853A1 (es)
HN (1) HN1998000045A (es)
HR (1) HRP980154B1 (es)
HU (1) HU225600B1 (es)
ID (1) ID29294A (es)
IL (1) IL131917A0 (es)
IS (1) IS2515B (es)
MY (1) MY116242A (es)
NO (1) NO326719B1 (es)
NZ (1) NZ337798A (es)
PA (1) PA8449301A1 (es)
PE (1) PE61699A1 (es)
PL (1) PL190505B1 (es)
PT (1) PT969815E (es)
RS (1) RS49772B (es)
SI (1) SI0969815T1 (es)
SK (1) SK283417B6 (es)
SV (1) SV1998000040A (es)
TW (1) TW536403B (es)
UY (1) UY24930A1 (es)
WO (1) WO1998042321A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4900074A1 (es) 1996-06-25 2000-03-27 Glaxo Group Ltd Combinaciones antivirales
US6018044A (en) * 1998-01-02 2000-01-25 Roche Vitamins Inc. Light screening compositions
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
US20040228804A1 (en) * 2003-05-16 2004-11-18 Jones Alonzo H. Nasal administration of xylitol to a non-human mammal
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
CN100427082C (zh) * 2005-08-02 2008-10-22 盛华（广州）医药科技有限公司 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用
GB2470494B (en) * 2008-01-17 2012-08-08 Univ Holy Ghost Duquesne Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
RU2587782C1 (ru) * 2015-01-19 2016-06-20 Общество с ограниченной ответственностью "Трейдсервис" Стабильная фармацевтическая композиция ламивудина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
EA199900757A1 (ru) 2000-08-28
CZ340399A3 (cs) 2000-04-12
JP2001501974A (ja) 2001-02-13
PL190505B1 (pl) 2005-12-30
KR20010005624A (ko) 2001-01-15
BR9808060B1 (pt) 2009-05-05
CO4980849A1 (es) 2000-11-27
AP1141A (en) 2003-01-29
PL336038A1 (en) 2000-06-05
CN1255849A (zh) 2000-06-07
AP9901657A0 (en) 1999-09-30
CZ298008B6 (cs) 2007-05-23
HRP980154B1 (en) 2002-06-30
NO994619D0 (no) 1999-09-23
HRP980154A2 (en) 1998-12-31
IS5184A (is) 1999-09-17
WO1998042321A3 (en) 1999-01-07
IL131917A0 (en) 2001-03-19
HUP0002982A3 (en) 2001-12-28
HN1998000045A (es) 1999-03-19
DE69830154T2 (de) 2005-10-13
RS49772B (sr) 2008-06-05
EA001990B1 (ru) 2001-10-22
SI0969815T1 (es) 2005-08-31
AR011697A1 (es) 2000-08-30
HK1022853A1 (en) 2000-08-25
NO994619L (no) 1999-11-23
IL131917A (en) 2001-01-11
DE69830154D1 (de) 2005-06-16
ES2239802T3 (es) 2005-10-01
BG64690B1 (bg) 2005-12-30
YU47799A (sh) 2002-06-19
BG103818A (en) 2000-06-30
UY24930A1 (es) 2000-10-31
US6004968A (en) 1999-12-21
MY116242A (en) 2003-12-31
WO1998042321A2 (en) 1998-10-01
HU225600B1 (en) 2007-05-02
EP0969815A2 (en) 2000-01-12
SK129999A3 (en) 2000-07-11
PA8449301A1 (es) 2000-05-24
SV1998000040A (es) 1999-03-16
SK283417B6 (sk) 2003-07-01
CY2569B1 (en) 2008-07-02
NO326719B1 (no) 2009-02-02
IS2515B (is) 2009-06-15
EE03996B1 (et) 2003-04-15
ATE295150T1 (de) 2005-05-15
EP0969815B1 (en) 2005-05-11
HUP0002982A2 (hu) 2001-01-29
EE9900440A (et) 2000-04-17
BR9808060A (pt) 2000-03-08
CA2286126C (en) 2003-08-12
CA2286126A1 (en) 1998-10-01
TW536403B (en) 2003-06-11
PT969815E (pt) 2005-07-29
ID29294A (id) 2001-08-16
JP3264937B2 (ja) 2002-03-11
KR100484695B1 (ko) 2005-04-22
NZ337798A (en) 2001-03-30
AU728461B2 (en) 2001-01-11
AU7208498A (en) 1998-10-20
CN1191061C (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
PE61699A1 (es) Composicion farmaceutica de lamivudina
BR0009485A (pt) Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
PE20000560A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
BR0015605A (pt) Composição e uso
AR071881A2 (es) Pestivirus atenuados
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
CO2022008701A2 (es) Uso y composición farmacéutica de derivados de fenilisoxazolil metilen-naftaleno-éter
BR0111678A (pt) Composições medicinais contendo derivados de propenona
AR018706A1 (es) Uso de una composicion farmaceutica para tratamiento de infecciones virales
TR200102024T2 (tr) Yeni tedavi.
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
PE20030303A1 (es) FORMULACIONES DE INTERFERON ß HUMANO
PE55694A1 (es) Medicamentos
SV1997000090A (es) Composiciones farmaceuticas.
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih
AR018707A1 (es) Composicion farmaceutica para tratar infecciones virales
KR900017587A (ko) 바이러스 감염증 치료제의 제조를 위한 티아졸 유도체 티프로티모드의 용도

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term